A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants with Huntington's Disease (INVEST-HD)

The purpose is to assess safety and tolerability of votoplam and to determine whether votoplam slows disease progression in patients with early symptomatic Huntington's disease (HD) compared to the control arm.

In order to participate you must meet the following criteria:

• Have signed informed consents obtained prior to participation in the study.
• Are an ambulatory male or female between 21 to 70 years of age, inclusive, on the day of Informed Consent signature.
• Have genetically confirmed HD diagnosis with a cytosine-adenine-guanine (CAG) repeat length of 40 or above. Participants must have prior genetic confirmation and known CAG repeat length obtained prior to screening.
• Have a UHDRS IS score ≥90.
• Have a UHDRS TFC score = 13.
• Have a UHDRS TMS score = 7-25, inclusive.
• Have a CAP100 ≥ 70 Calculation: CAP = Age at study entry × (CAG length - 30) / 6.49.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.